의료진프로필

The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population

Bak, M; Park, H; Lee, SH; Lee, N; Ahn, MJ; Ahn, JS; Jung, HA; Park, S; Cho, J; Kim, J; Park, SJ; Chang, SA; Lee, SC; Park, SW; Kim, EK

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer

Shin, JE; Jung, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Shim, BY

Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis

Kim, Y; Choi, N; Kim, EH; Chung, MK; Son, YI; Oh, D; Ahn, YC; Lee, SH; Jung, HA; Park, S; Kim, J; Jeong, HS; Ahn, MJ

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

Lee, SH; Menis, J; Kim, TM; Kim, HR; Zhou, C; Kurniawati, SA; Prabhash, K; Hayashi, H; Lee, DDW; Imasa, MS; Teh, YL; Yang, JCH; Reungwetwattana, T; Sriuranpong, V; Wu, CE; Ang, Y; Sabando, M; Thiagarajan, M; Mizugaki, H; Noronha, V; Yulianti, M; Zhang, L; Smyth, E; Yoshino, T; Park, JO; Pentheroudakis, G; Park, S; Peters, S; Ahn, JB; Popat, S

Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma

Hong, MH; Park, S; Vo, T; Cho, J; Jung, HA; Lee, SH; Kim, SH; Zhou, H; Chirovsky, D; Koh, YW; Yoon, SO; Webber, AL; Gumuscu, B; Cho, BC; Ahn, MJ

Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer

Kim, YG; Lee, B; Ha, C; Lee, C; Jung, HA; Sun, JM; Lee, SH; Ahn, MJ; Choi, YL; Park, S; Kim, JW

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAF V600E-Mutated Thyroid Cancer

Jeon, Y; Park, S; Lee, SH; Kim, TH; Kim, SW; Ahn, MJ; Jung, HA; Chung, JH

Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial

Shin, J; Park, S; Kim, KH; Shin, EC; Jung, HA; Cho, JH; Sun, JM; Lee, SH; Choi, YS; Ahn, JS; Kim, J; Park, K; Shim, YM; Kim, HK; Noh, JM; Ahn, YC; Pyo, H; Ahn, MJ

Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)

Park, S; Baldry, R; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Kim, YJ; Lee, Y; Kim, DW; Kim, SW; Lee, KH; Lee, WJ; Choi, JW; Chong, K; Lee, JI; Gwon, SH; Son, NH; Ahn, MJ

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP

Kim, M; Shim, HS; Kim, S; Lee, IH; Kim, J; Yoon, S; Kim, HD; Park, I; Jeong, JH; Yoo, C; Cheon, J; Kim, IH; Lee, J; Hong, SH; Park, S; Jung, HA; Kim, JW; Kim, HJ; Cha, Y; Lim, SM; Kim, HS; Lee, CK; Kim, JH; Chun, SH; Yun, J; Park, SY; Lee, HS; Cho, YM; Nam, SJ; Na, K; Yoon, SO; Lee, A; Jang, KT; Yun, H; Lee, S; Kim, JH; Kim, WS

Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer

Jung, YJ; Ahn, J; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, SY; Jung, HA

Evaluating the effect of a mobile-based symptom monitoring system for improving physical function in patients with cancer during chemotherapy: study protocol for a multicentre randomised controlled trial

Lee, M; Kang, D; Um, Y; Jo, B; Rhue, J; Park, S; Lee, Y; Noh, JJ; Lee, YG; Koo, DH; Park, KH; Lee, S; Ahn, JS; Oh, D; Cho, J

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Park, S; Kim, TM; Han, JY; Lee, GW; Shim, BY; Lee, YG; Kim, SW; Kim, IH; Lee, S; Kim, YJ; Park, JH; Park, SG; Lee, KH; Kang, EJ; Kim, JW; Shin, SH; Ock, CY; Nam, BH; Lee, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ

Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis

Jung, HA; Park, B; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ

Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer

Park, S; Hong, TH; Hwang, S; Heeke, S; Gay, CM; Kim, J; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Cho, JH; Choi, YS; Kim, J; Shim, YM; Kim, HK; Byers, LA; Heymach, JV; Choi, YL; Lee, SH; Park, K

Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer

Kim, H; Kim, S; Choi, S; Park, C; Park, S; Pereira, S; Ma, MN; Yoo, D; Paeng, K; Jung, WKY; Park, S; Ock, CY; Lee, SH; Choi, YL; Chung, JH

Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study

Park, S; Lee, Y; Lee, J; Min, YW; Kim, HK; Choi, JY; Jung, HA; Choi, YS; Choi, YL; Shim, YM; Sun, JM

Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses

Park, S; Kang, JK; Lee, N; Lee, SH; Kim, HP; Kim, SY; Kim, TY; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

Shen, JN; Choi, YL; Lee, T; Kim, H; Chae, YK; Dulken, B; Bogdan, S; Huang, M; Fisher, GA; Park, S; Lee, SH; Hwang, JE; Chung, JH; Kim, L; Song, H; Pereira, S; Shin, S; Lim, Y; Ahn, CH; Kim, S; Oum, C; Kim, S; Park, G; Song, S; Jung, W; Kim, S; Bang, YJ; Mok, TSK; Ali, SM; Ock, CY

First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data

Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ

Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B

Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ

PD-L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system

Hwang, S; Hong, TH; Kim, HK; Cho, J; Lee, G; Choi, S; Park, S; Lee, SH; Lee, Y; Jeon, YJ; Lee, J; Park, SY; Cho, JH; Choi, YS; Kim, J; Zo, JI; Shim, YM; Choi, YL

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study

Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)

Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH

Prognostic significance of body mass index in small-cell lung cancer: Exploring the relationship with skeletal muscle status

Kwon, YJ; Yoon, YC; Kim, HS; Cha, MJ; Park, S; Lee, JH

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA

Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer

Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K

Increasing discrepancy of MR imaging and CSF study in patients with leptomeningeal seeding from lung adenocarcinoma after targeted therapy using a tyrosine kinase inhibitor

Seong, M; Park, S; Kim, ST; Park, SG; Kim, Y; Cha, J; Kim, EY; Kim, HJ; Ahn, MJ

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Kim, H; Park, S; Jung, HA; Lee, SH; Park, K; Ahn, YC; Oh, D; Ahn, MJ

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer

Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer

Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH

Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group

Loong, HH; Shimizu, T; Prawira, A; Tan, AC; Tran, B; Day, D; Tan, DSP; Ting, FIL; Chiu, JW; Hui, M; Wilson, MK; Prasongsook, N; Koyama, T; Reungwetwattana, T; Tan, TJ; Heong, V; Voon, PJ; Park, S; Tan, IB; Chan, SL; Tan, DSW

Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: a randomized controlled trial

Lee, M; Kang, D; Kang, E; Kim, S; Kim, Y; Ahn, JS; Park, S; Lee, YY; Oh, D; Noh, JM; Cho, JH

A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas

Lee, J; Park, S; Jung, HA; Lee, SH; Seo, S; Kim, SB; Kim, JW; Lee, KW; Kang, EJ; Kim, JW; Choi, YJ; Shim, BY; An, HJ; Park, LC; Shin, SH; Kim, JJ; Oh, SY; Kim, MK; Ahn, MJ

Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance

Hwang, S; Hong, TH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Han, J; Ahn, YC; Pyo, H; Noh, JM; Lee, HY; Kim, HJ; Park, S; Ahn, MJ; Park, K; Lee, SH; Choi, YL; Kim, J

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma

Lee, MS; An, S; Song, JY; Sung, M; Jung, K; Chang, ES; Choi, J; Oh, DY; Jeon, YK; Yang, H; Lakshmi, C; Park, S; Han, J; Lee, SH; Choi, YL

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis

Jung, JY; Heo, YJ; Park, S

EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis

Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ

Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells

Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW

Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020

Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K

Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma

Hong, TH; Hwang, S; Choi, YL; Lee, GEH; Park, S; Ahn, MJ; Lee, Y; Jeon, YJ; Lee, J; Shin, S; Park, SY; Cho, JH; Choi, YS; Kim, J; Shim, YM; Cho, JH; Kim, HK

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment

Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI

Kim, HR; Jo, H; Kim, H; Hong, J; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ

Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer

Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)

Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma

Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer

Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC

Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K

Prognostic value of FOXP3+regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

Hur, JY; Ku, BM; Park, S; Jung, HA; Lee, SH; Ahn, MJ

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma

Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH

Metabolic parameters on baseline F-18-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma

Kwon, HR; Cho, JH; Park, S; Lee, SH; Ahn, MJ; Choi, JY; Lee, KH; Jung, HA; Moon, SH

Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial

Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study

Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer

Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH

Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1

Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC

Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer

Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Park, S; Oh, D; Choi, YL; Chi, SA; Kim, K; Ahn, MJ; Sun, JM

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study

Park, S; Sun, JM; Choi, YL; Oh, D; Kim, HK; Lee, T; Chi, SA; Lee, SH; Choi, YS; Jung, SH; Ahn, MJ; Ahn, YC; Park, K; Shim, YM

Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment

Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Lung Cancer in Korea

Park, S; Choi, CM; Hwang, SS; Choi, YL; Kim, HY; Kim, YC; Kim, YT; Lee, HY; Song, SY; Ahn, MJ

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience

Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment

Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH

Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system

Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer

Park, S; Lee, C; Ku, BM; Kim, M; Park, WY; Kim, NKD; Ahn, MJ

Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer

Sehhoon Park ¹, Eunjin Lee , Seri Park , Sohee Lee , Seok Jin Nam , Seok Won Kim , Jeong Eon Lee , Jong-Han Yu , Ji-Yeon Kim , Jin Seok Ahn , Young-Hyuck Im , Woong-Yang Park , Kyunghee Park , Yeon Hee Park

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Jiyun Lee ¹, Sehhoon Park , Hyun Ae Jung , Jong-Mu Sun , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park , Myung-Ju Ahn

Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR

Minjung Seong ¹, Sehhoon Park , Sung Tae Kim , Sung Goo Park , Yi Kyung Kim , Hyung-Jin Kim , Myung-Ju Ahn

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Sehhoon Park ¹, Bo Mi Ku , Hyun Ae Jung , Jong-Mu Sun , Jin Seok Ahn , Se-Hoon Lee , Keunchil Park , Myung-Ju Ahn

Biomarker?driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum?based chemotherapy

Sehhoon Park ¹, Joonho Shim , Peter G S Mortimer , Simon A Smith , Robert E Godin , Simon J Hollingsworth , Hee-Jung Kim , Hyun Ae Jung , Jong-Mu Sun , Woong-Yang Park , Jin Seok Ahn , Myung-Ju Ahn , Se-Hoon Lee , Keunchil Park

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

S Park ¹, M-H Lee , M Seong , S T Kim , J-H Kang , B C Cho , K H Lee , E K Cho , J-M Sun , S-H Lee , J S Ahn , K Park , M-J Ahn

Osimertinib in central nervous system progressive EGFR-mutant lung cancer do we need to detect T790M?

Park¹, S; Ahn, MJ

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Lee¹, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations?

Jung¹, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Park¹, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Park¹, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Hong¹, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY

Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal added value of contrast-enhanced 2D axial T2 FLAIR

Seong¹, M; Park, S; Kim, ST; Park, SG; Kim, YK; Kim, HJ; Ahn, MJ

Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer

Park¹, S; Lee, E; Park, S; Lee, S; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Kim, JY; Ahn, JS; Im, YH; Park, WY; Park, K; Park, YH

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy

Park¹, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Lee¹, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.

Sehhoon Park ¹, Se-Hoon Lee , Keunchil Park

Clinical characteristics and combined somatic mutation using target sequencing among breast cancer patients with germline BRCA mutation

Park Sehhoon¹, Lee Eunjin, Park Seri, Lee Sohee, Hur Joon Young, Yoon Sang Eun, Lee Kangkook, Cho Jang Ho, Kim Ji-Yeon, Ahn Jin Seok

DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC

Sehhoon Park ¹, Hayoon Lee , Boram Lee , Se-Hoon Lee , Jong-Mu Sun , Woong-Yang Park , Jin Seok Ahn , Myung-Ju Ahn , Keunchil Park

Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor

Sehhoon Park ¹, Joungho Han , Jong-Mu Sun

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial

Sung Won Lim ¹, Sehhoon Park , Youjin Kim , Jang Ho Cho , Song Ee Park , Hansang Lee , Hee Kyung Kim , Sung Min Kim , Jong Mu Sun , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park , Myung-Ju Ahn

Characteristics and outcome of ROS1-positive non?small cell lung cancer patients in routine clinical practice

Sehhoon Park ¹, Beung-Chul Ahn , Sung Won Lim , Jong-Mu Sun , Hye Ryun Kim , Min Hee Hong , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park , Yoon La Choi , Byoung Chul Cho , Myung-Ju Ahn

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor

Sehhoon Park ¹, Seunggyun Ha , Se-Hoon Lee , Jin Chul Paeng , Bhumsuk Keam , Tae Min Kim , Dong-Wan Kim , Dae Seog Heo

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer

Sehhoon Park ¹, Ji-Yeon Kim , Se-Hoon Lee , Beomseok Suh , Bhumsuk Keam , Tae Min Kim , Dong-Wan Kim , Dae Seog Heo

Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma

J-K Lee ¹, S Louzada , Y An , S Y Kim , S Kim , J Youk , S Park , S H Koo , B Keam , Y K Jeon , J-L Ku , F Yang , T M Kim , Y S Ju

Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma

Yeonghun Lee ¹, Sehhoon Park , Se-Hoon Lee , Hyunju Lee

Early repolarization is associated with significant coronary artery stenosis in asymptomatic adults

Beomseok Suh ¹, Sehhoon Park , Dong Wook Shin , Hongkeun Ahn , Seongcheol Cho , Seung-Pyo Lee , Eun-Ah Park , Hyejin Lee , Jin Ho Park , BeLong Cho

Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome

Sehhoon Park ¹, Hwi Young Kim, Haeryoung Kim, Jin Hyun Park, Jung Ho Kim, Ki Hwan Kim, Won Kim, In Sil Choi, Yong Jin Jung, Jin-Soo Kim

A case of statin-induced interstitial pneumonitis due to rosuvastatin

Se Yong Kim ¹, Se Jin Kim , Doran Yoon , Seung Wook Hong , Sehhoon Park , Chan-Young Ock

High liver fibrosis index FIB?4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers

Beomseok Suh ¹, Sehhoon Park, Dong Wook Shin, Jae Moon Yun, Hyung-Kook Yang, Su Jong Yu, Cheong-Il Shin, Jin-Soo Kim, Eunmi Ahn, Hyejin Lee, Jin Ho Park, BeLong Cho